Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Adalimumab

Criteria

Inclusion Criteria:

• Diagnosis of moderate to severe chronic plaque psoriasis

• Active psoriasis, despite topical therapies

Exclusion Criteria:

• Other active skin diseases or skin infections

• Prior exposure to any anti-TNF therapy

• Subject has other active skin diseases

• Multiple concomitant therapy restrictions and/or washouts (topicals, UV, other systemic PS therapies)

• Poorly controlled medical conditions

• History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease

• History of cancer or lymphoproliferative disease

• History of active TB or listeriosis, or persistent chronic or active infections

• Known to have immune deficiency or is immunocompromised

• Clinically significant abnormal laboratory test results

• Erythrodermic psoriasis or generalized pustular psoriasis